Phase I Study in RAD 001 Patients With Relapse AML

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A phase I clinical study in evaluation of RAD 001 with aracytine and daunorubicine in AML treatment of patients older less than 65 years in relapse

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: French Innovative Leukemia Organisation
• Collaborator: Novartis Pharmaceuticals
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

• patients from 18 to 65 years old

• AML in relapse more than 1 year after CR

• inform consent signed

Exclusion Criteria:

• age more than 65

• cardiac insufficiency

• renal insufficiency

• hepatic disease

• other type of AML

• blastic MCL

• HIV positive serology

• other malignancy

• pulmonary infection